Accelr8 Technology Corporation Announces Interim Plan and Advanced Studies

Published: Oct 13, 2011

DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (NYSE Amex: AXK) announced that upon reaching the end of its technology evaluation agreement with Novartis (Sep 30, 2011), discussion has now shifted to searching within Novartis for funding vehicles. This transition follows Novartis business analyses and successful Proof of Concept technical studies conducted jointly between the companies. Accelr8’s management concluded that in addition to successful technical studies, the findings from a number of independent business analyses and advisory boards have been concordant with Accelr8’s market assessments and pricing assumptions.

Back to news